Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
P/E ratio for Seer, Inc. (SEER)
P/E ratio as of 2023: -1.44
According to Seer, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.44. At the end of 2022 the company had a P/E ratio of -4.08.
P/E ratio history for Seer, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.44 |
| 2022 | -4.08 |
| 2021 | -20.23 |
| 2020 | -109.71 |
| 2019 | -214.36 |
| 2018 | -192.06 |